269 related articles for article (PubMed ID: 17293088)
1. Ertapenem resistance among Klebsiella and Enterobacter submitted in the UK to a reference laboratory.
Woodford N; Dallow JW; Hill RL; Palepou MF; Pike R; Ward ME; Warner M; Livermore DM
Int J Antimicrob Agents; 2007 Apr; 29(4):456-9. PubMed ID: 17293088
[TBL] [Abstract][Full Text] [Related]
2. Molecular mechanisms disrupting porin expression in ertapenem-resistant Klebsiella and Enterobacter spp. clinical isolates from the UK.
Doumith M; Ellington MJ; Livermore DM; Woodford N
J Antimicrob Chemother; 2009 Apr; 63(4):659-67. PubMed ID: 19233898
[TBL] [Abstract][Full Text] [Related]
3. [Investigation of carbapenemases in carbapenem-resistant Escherichia coli and Klebsiella pneumoniae strains isolated in 2014 in Turkey].
Çakar A; Akyön Y; Gür D; Karatuna O; Öğünç D; Özhak Baysan B; Çöplü N; Çağatay M; Kılıç A; Baysallar M; Bakıcı Z; Çelik C; Gülay Z; Aydemir Ş; Tünger A; Kılıç H; Erçal BD; Aşçı Toraman Z; Zer Y; Büyüktaş A; Ay S; Aktaş Z; Kayacan Ç; Bayramoğlu G; Aydın F; Dündar D; Hasdemir U; Ayaş R; Yanık K; Günaydın M; Güdücüoğlu H; Parlak M
Mikrobiyol Bul; 2016 Jan; 50(1):21-33. PubMed ID: 27058326
[TBL] [Abstract][Full Text] [Related]
4. In vitro activities of three carbapenems against recent bacterial isolates from severely ill patients at Swedish hospitals.
Fraenkel CJ; Ullberg M; Bernander S; Ericson E; Larsson P; Rydberg J; Törnqvist E; Melhus A
Scand J Infect Dis; 2006; 38(10):853-9. PubMed ID: 17008228
[TBL] [Abstract][Full Text] [Related]
5. Carbapenem MICs in Escherichia coli and Klebsiella Species Producing Extended-Spectrum β-Lactamases in Critical Care Patients from 2001 to 2009.
Johnson JK; Robinson GL; Pineles LL; Ajao AO; Zhao L; Albrecht JS; Harris AD; Thom KA; Furuno JP
Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167543
[TBL] [Abstract][Full Text] [Related]
6. [Carbapenem resistance in ESBL positive Enterobacteriaceae isolates causing invasive infections].
Eser OK; Altun Uludağ H; Ergin A; Boral B; Sener B; Hasçelik G
Mikrobiyol Bul; 2014 Jan; 48(1):59-69. PubMed ID: 24506716
[TBL] [Abstract][Full Text] [Related]
7. Non-susceptibility trends among Enterobacteriaceae from bacteraemias in the UK and Ireland, 2001-06.
Livermore DM; Hope R; Brick G; Lillie M; Reynolds R;
J Antimicrob Chemother; 2008 Nov; 62 Suppl 2():ii41-54. PubMed ID: 18819979
[TBL] [Abstract][Full Text] [Related]
8. Prevalence and characterization of extended spectrum β-lactamases in Klebsiella-Enterobacter-Serratia group bacteria, in Algeria.
Nedjai S; Barguigua A; Djahmi N; Jamali L; Zerouali K; Dekhil M; Timinouni M
Med Mal Infect; 2012 Jan; 42(1):20-9. PubMed ID: 22056377
[TBL] [Abstract][Full Text] [Related]
9. Comparative activities of doripenem versus isolates, mutants, and transconjugants of Enterobacteriaceae and Acinetobacter spp. with characterized beta-lactamases.
Mushtaq S; Ge Y; Livermore DM
Antimicrob Agents Chemother; 2004 Apr; 48(4):1313-9. PubMed ID: 15047535
[TBL] [Abstract][Full Text] [Related]
10. Porin alterations present in non-carbapenemase-producing Enterobacteriaceae with high and intermediate levels of carbapenem resistance in Chile.
Wozniak A; Villagra NA; Undabarrena A; Gallardo N; Keller N; Moraga M; Román JC; Mora GC; García P
J Med Microbiol; 2012 Sep; 61(Pt 9):1270-1279. PubMed ID: 22700549
[TBL] [Abstract][Full Text] [Related]
11. Assessment of extended-spectrum β-lactamase, KPC carbapenemase and porin resistance mechanisms in clinical samples of Klebsiella pneumoniae and Enterobacter spp.
Jaskulski MR; Medeiros BC; Borges JV; Zalewsky R; Fonseca ME; Marinowic DR; Rocha MP; Nodari P; Machado DC
Int J Antimicrob Agents; 2013 Jul; 42(1):76-9. PubMed ID: 23664677
[TBL] [Abstract][Full Text] [Related]
12. What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline.
Livermore DM; Warner M; Mushtaq S; Doumith M; Zhang J; Woodford N
Int J Antimicrob Agents; 2011 May; 37(5):415-9. PubMed ID: 21429716
[TBL] [Abstract][Full Text] [Related]
13. Activity of ertapenem (MK-0826) versus Enterobacteriaceae with potent beta-lactamases.
Livermore DM; Oakton KJ; Carter MW; Warner M
Antimicrob Agents Chemother; 2001 Oct; 45(10):2831-7. PubMed ID: 11557477
[TBL] [Abstract][Full Text] [Related]
14. Pharmacodynamic modeling of carbapenems and fluoroquinolones against bacteria that produce extended-spectrum beta-lactamases.
Moczygemba LR; Frei CR; Burgess DS
Clin Ther; 2004 Nov; 26(11):1800-7. PubMed ID: 15639692
[TBL] [Abstract][Full Text] [Related]
15. Wide geographic spread of diverse acquired AmpC beta-lactamases among Escherichia coli and Klebsiella spp. in the UK and Ireland.
Woodford N; Reddy S; Fagan EJ; Hill RL; Hopkins KL; Kaufmann ME; Kistler J; Palepou MF; Pike R; Ward ME; Cheesbrough J; Livermore DM
J Antimicrob Chemother; 2007 Jan; 59(1):102-5. PubMed ID: 17110393
[TBL] [Abstract][Full Text] [Related]
16. Sustained activity and spectrum of selected extended-spectrum beta-lactams (carbapenems and cefepime) against Enterobacter spp. and ESBL-producing Klebsiella spp.: report from the SENTRY antimicrobial surveillance program (USA, 1997-2000).
Jones RN; Biedenbach DJ; Gales AC
Int J Antimicrob Agents; 2003 Jan; 21(1):1-7. PubMed ID: 12507831
[TBL] [Abstract][Full Text] [Related]
17. Activity of BAL30072 alone or combined with β-lactamase inhibitors or with meropenem against carbapenem-resistant Enterobacteriaceae and non-fermenters.
Mushtaq S; Woodford N; Hope R; Adkin R; Livermore DM
J Antimicrob Chemother; 2013 Jul; 68(7):1601-8. PubMed ID: 23449829
[TBL] [Abstract][Full Text] [Related]
18. Molecular Characterization of Carbapenem-Nonsusceptible Enterobacterial Isolates Collected during a Prospective Interregional Survey in France and Susceptibility to the Novel Ceftazidime-Avibactam and Aztreonam-Avibactam Combinations.
Dupont H; Gaillot O; Goetgheluck AS; Plassart C; Emond JP; Lecuru M; Gaillard N; Derdouri S; Lemaire B; Girard de Courtilles M; Cattoir V; Mammeri H
Antimicrob Agents Chemother; 2016 Jan; 60(1):215-21. PubMed ID: 26482307
[TBL] [Abstract][Full Text] [Related]
19. [Genetic determinants of antibacterial resistance among nosocomial Escherichia coli, Klebsiella spp., and Enterobacter spp. isolates collected in Russia within 2003-2007].
Priamchuk SD; Fursova NK; Abaev IV; Kovalev IuN; Shishkova NA; Pecherskikh EI; Korobova OV; Astashkin EI; Pachkunov DM; Kruglov AN; Ivanov DV; Sidorenko SV; Svetoch EA; Diatlov IA
Antibiot Khimioter; 2010; 55(9-10):3-10. PubMed ID: 21400746
[TBL] [Abstract][Full Text] [Related]
20. Collateral damage of flomoxef therapy: in vivo development of porin deficiency and acquisition of blaDHA-1 leading to ertapenem resistance in a clinical isolate of Klebsiella pneumoniae producing CTX-M-3 and SHV-5 beta-lactamases.
Lee CH; Chu C; Liu JW; Chen YS; Chiu CJ; Su LH
J Antimicrob Chemother; 2007 Aug; 60(2):410-3. PubMed ID: 17576696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
